Johnson & Johnson

Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.


J&J recalling 12 million bottles of Mylanta

Johnson & Johnson is adding 12 million bottles of Mylanta — the stomach discomfort treatment — to its ongoing list of recalled products, due to the presence of alcohol that’s not listed on the label.

J&J said it is recalling more than 12.3 million bottles of Mylanta and more than 84,000 bottles of AlternaGel, which is used for heartburn relief.
Get the full story »

J&J pulls more Tylenol over labeling problem

Johnson & Johnson, which has been recalling a number of popular over-the-counter medicines, said Wednesday it’s withdrawing more Tylenol because of a labeling problem.

The company’s McNeil Consumer Healthcare unit is recalling nearly 9.3 million bottles of three Tylenol Cold Multi-Symptom products from drug stores and suppliers because the bottles’ front labels didn’t show they contain small amounts of alcohol from ingredients that flavor the medicine. Get the full story »

J&J recalls children’s Benadryl Fastmelt, junior Motrin

Health care giant Johnson & Johnson is announcing another product recall, this one involving some Children’s Benadryl Allergy Fastmelt Tablets and Junior Strength Motrin Caplets. Get the full story »

Children’s Benedryl recall latest to hit J&J

Johnson & Johnson has recalled about 4 million packages of children’s Benadryl allergy tablets and about 800,000 bottles of junior-strength Motrin, citing “insufficiencies” in developing the manufacturing process.

It was the latest in a series of product recalls in the last year that have hurt the reputation and financial results of J&J. Get the full story »

Bayer, J&J anti-clot drug shines in stroke trial

A once-daily pill being developed by Bayer AG and Johnson & Johnson was better at preventing stroke than standard treatment, with less risk of the most worrisome types of bleeding, researchers said on Monday. Get the full story »

Bayer, J&J blood pill shows mass-market promise

A new stroke prevention drug developed by Bayer and Johnson & Johnson proved a safe alternative to the standard treatment, lifting their chances of entering a $12 billion plus market, the German drug company said.

A late-stage study called Rocket-AF showed that the Xarelto pill was as good as the established warfarin pill at reducing the risk of strokes due to a form of irregular heartbeat that is common among the elderly, Bayer said on Sunday. Get the full story »

J&J makes another Tylenol recall

Johnson & Johnson is recalling yet another lot of over-the-counter Tylenol because of a musty or moldy smell. McNeil Consumer Healthcare business says it is recalling lot BCM155, or about 128,000 bottles, of Tylenol 8 Hour caplets that come in bottles with 50 pills. Get the full story »

FDA seeks more data on J&J pain treatment

U.S. health regulators have requested more data on Johnson & Johnson’s chronic pain treatment before they will approved the product, the company said Monday.

The Food and Drug Administration sent J&J a complete response letter for J&J’s tapentadol extended release tablets. Get the full story »

FDA warns Walgreens about mouthwash claims

The Food and Drug Administration on Tuesday warned Johnson & Johnson, CVS and Walgreens to stop making “unproven“ claims that their mouthwash products are effective in removing plaque or preventing gum disease.

In a warning letter sent to each company, regulators specifically targeted Johnson & Johnson’s “Listerine Total Care Anticavity Mouthwash“, CVS’s “CVS Complete Care Anticavity Mouthwash“ and Walgreen’s “Walgreen Mouth Rinse Full Action.” Get the full story »

Amgen recalls anemia drugs over glass concerns

Amgen Inc. is recalling hundred of lots of anemia drugs Epogen and Procrit, sold by Johnson & Johnson, because vials of the injectable medicines might develop tiny glass flakes that could cause blood clots and other serious health problems.

Amgen, which sells Epogen, makes the identical drugs at a plant in Puerto Rico. Get the full story »

J&J lawyers: U.S. knew of Motrin ‘phantom recall’

U.S. health regulators knew that Johnson & Johnson’s McNeil unit was using a contractor to buy back potentially faulty batches of Motrin, though there was no formal agreement with the government, lawyers for the company told lawmakers.

Still, in a letter to the House Oversight and Government Reform Committee Wednesday, J&J’s lawyers said though the purchases of defective painkiller  from retailers were legal, “moving forward the company would handle things differently.” Get the full story »

J&J eyes vaccine maker Crucell

U.S. health care company Johnson & Johnson, looking to catapult itself into the global vaccine market, is in talks to pay $2.3 billion to buy Dutch biotech Crucell. Get the full story »

Buffett’s Berkshire trims Kraft, doubles J&J

Warren Buffett’s company has partially rebuilt the stake in Johnson & Johnson he reduced over the past two years to raise cash for other investments, and Berkshire Hathaway Inc. boosted its investment in Wal-Mart Stores Inc. during the second quarter. Berkshire detailed its $46.4 billion U.S. stock holdings Monday in a filing with the Securities and Exchange Commission.

The document revealed several changes in the Omaha-based company’s portfolio between March 31 and the end of June, including decreases in Berkshire’s holdings in Kraft Foods, ConocoPhillips, Procter & Gamble and M&T Bank. Berkshire also increased its stakes in Becton Dickinson & Co., Nalco Holding Co. and Sanofi Aventis. Get the full story »

J&J discloses more subpoenas over recalls

Johnson & Johnson disclosed Wednesday that the health products giant has now received multiple subpoenas from federal prosecutors related to repeated recalls of Tylenol and other consumer health products. Get the full story »

Success with wireless diabetes monitor reported

Researchers have developed an implantable sensor that measures blood sugar continuously and transmits the information without wires — a milestone, they said, in diabetes treatment.

The device worked in one pig for more than a year and in another for nearly 10 months with no trouble, said a report in the journal Science Translational Medicine. Get the full story »